Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

This prospective clinical study compares patient-reported outcome measures (PROMs) after adaptive or conventional radiotherapy in prostate cancer. Adaptive radiotherapy (ART) aims to reduce uncertainties related to daily anatomical variations, thereby improving treatment accuracy while decreasing gastrointestinal (GI) and genitourinary (GU) toxicity. This study, conducted at Cliniques universitaires Saint-Luc (Brussels and Ottignies sites), analyzes and compares toxicities in patients treated with ART on Ethos and those treated with conventional radiotherapy on Halcyon. The primary objective

Trial Details

NCT ID
NCT07245745
Phase
NA
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Radiotherapy
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878

Key Eligibility Criteria

  • Patients with prostate cancer referred for curative-intent radiotherapy
  • Male patients ≥ 18 years old
  • ECOG performance status 0-1
  • Patients willing to use an e-health application

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →